BELITE BIO, INC Logo

BELITE BIO, INC

Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.

BLTE | US

Overview

Corporate Details

ISIN(s):
US07782B1044
LEI:
Country:
United States of America
Address:
12750 HIGH BLUFF DRIVE SUITE 475, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Belite Bio, Inc. is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. The company's primary targets include atrophic age-related macular degeneration (specifically Geographic Atrophy, or GA) and Stargardt disease (STGD1). Its therapeutic pipeline is built on a proprietary portfolio targeting Retinol Binding Protein 4 (RBP4). The lead candidate, Tinlarebant (LBS-008), is a novel oral therapy designed to reduce the accumulation of ocular toxins that contribute to disease progression. Tinlarebant is in late-stage development with multiple Phase 3 trials and has received numerous regulatory designations, including Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations in the U.S. and other key markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BELITE BIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BELITE BIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BELITE BIO, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America INBX
InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America INM
Inmune Bio, Inc. Logo
Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.
United States of America INMB
Innate Pharma SA Logo
Developing first-in-class antibody immunotherapies for cancer via the innate immune system.
United States of America IPHA
INOVIO PHARMACEUTICALS, INC. Logo
Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.
United States of America INO
Insight Molecular Diagnostics Inc. Logo
Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.
United States of America IMDX
INSMED Inc Logo
Develops and commercializes innovative therapies for serious and rare diseases.
United States of America INSM
Instil Bio, Inc. Logo
Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.
United States of America TIL
Intellia Therapeutics, Inc. Logo
Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.
United States of America NTLA

Talk to a Data Expert

Have a question? We'll get back to you promptly.